incontestable
发表于 2025-3-21 16:59:21
书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia影响因子(影响力)<br> http://figure.impactfactor.cn/if/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia影响因子(影响力)学科排名<br> http://figure.impactfactor.cn/ifr/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia网络公开度<br> http://figure.impactfactor.cn/at/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia网络公开度学科排名<br> http://figure.impactfactor.cn/atr/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia被引频次<br> http://figure.impactfactor.cn/tc/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia被引频次学科排名<br> http://figure.impactfactor.cn/tcr/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia年度引用<br> http://figure.impactfactor.cn/ii/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia年度引用学科排名<br> http://figure.impactfactor.cn/iir/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia读者反馈<br> http://figure.impactfactor.cn/5y/?ISSN=BK0638447<br><br> <br><br>书目名称Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia读者反馈学科排名<br> http://figure.impactfactor.cn/5yr/?ISSN=BK0638447<br><br> <br><br>
Cleave
发表于 2025-3-21 20:23:50
ence of TKIs such as imatinib, nilotinib, dasatinib, and pon.Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia provides a comprehensive understanding of the recent molecular genetics of Chronic Myelogenous Leukemia (CML) and a characterization of the molecular targets for drug dev
scoliosis
发表于 2025-3-22 00:48:21
http://reply.papertrans.cn/64/6385/638447/638447_3.png
FLIRT
发表于 2025-3-22 04:56:31
http://reply.papertrans.cn/64/6385/638447/638447_4.png
噱头
发表于 2025-3-22 11:02:37
Masahiro KizakiIs a comprehensive, high-level clinical reference on the pathogenesis and therapy of hematological malignancies.Provides the clinical experience of TKIs such as imatinib, nilotinib, dasatinib, and pon
ENNUI
发表于 2025-3-22 16:01:24
Book 2016 these, including tyrosine kinase inhibitors such as imatinib, nilotinib, and dasatinib, lead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML..
DAMP
发表于 2025-3-22 18:09:00
ead to increased survival rates and improved therapies. With the opinion leaders of basic and clinical research in the field as authors, this book reviews recent advances in the biology of CML..978-4-431-56255-9978-4-431-55714-2
Cabg318
发表于 2025-3-23 01:04:07
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia
brassy
发表于 2025-3-23 04:00:22
Molecular Pathogenesis and Treatment of Chronic Myelogenous Leukemia978-4-431-55714-2
软膏
发表于 2025-3-23 08:40:48
http://reply.papertrans.cn/64/6385/638447/638447_10.png